Ardelyx Stock Climbs on Raised FY Revenue Outlook for IBS Treatment

Dow Jones10-31

By Kelly Cloonan

Shares of Ardelyx rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand.

The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year.

The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously.

The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said.

For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share.

Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million.

The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 31, 2025 11:53 ET (15:53 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579982499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 23:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579982499","market":"other","top_or_hot":-1,"title":"Ardelyx Stock Climbs on Raised FY Revenue Outlook for IBS Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand. \n</p>\n<p>\n  The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year. \n</p>\n<p>\n  The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. \n</p>\n<p>\n  The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said. \n</p>\n<p>\n  For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share. \n</p>\n<p>\n  Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million. \n</p>\n<p>\n  The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2025 11:53 ET (15:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx Stock Climbs on Raised FY Revenue Outlook for IBS Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx Stock Climbs on Raised FY Revenue Outlook for IBS Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-31 23:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a> rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand. \n</p>\n<p>\n  The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year. \n</p>\n<p>\n  The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. \n</p>\n<p>\n  The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said. \n</p>\n<p>\n  For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share. \n</p>\n<p>\n  Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million. \n</p>\n<p>\n  The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2025 11:53 ET (15:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2579982499","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579982499","pubTimestamp":1761925980,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Ardelyx rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand.The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year.The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously.The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said.For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share.Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million.The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"Ardelyx股价因IBS治疗财年收入前景上调而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Ardelyx rose after the company raised its full-year revenue guidance for its irritable bowel syndrome treatment due to strong demand. \n\n\n  The stock climbed 22% to $6.11 on Friday. Shares are up 21% this year. \n\n\n  The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. \n\n\n  The updated outlook comes as Ibsrela continues to post strong growth due to sustained demand from IBS patients with constipation, the company said. \n\n\n  For the third quarter, the company posted a loss of $969,000, or 0 cents a share, compared with a loss of $809,000, or 0 cents a share, a year earlier. Analysts polled by FactSet had forecast a loss of 6 cents a share. \n\n\n  Revenue rose to $110.3 million compared with $98.2 million a year ago. Analysts had expected $100.5 million. \n\n\n  The growth was led by Ibsrela, up 92% to $78.2 million. Xphozah revenue declined to $27.4 million due to a loss of Medicare coverage, the company said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2025 11:53 ET (15:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579982499","isCrawlerRequest":true}